表紙
市場調查報告書

全基因&EXOME定序的全球市場:研究、臨床、DTC、農業生物技術、癌細胞用途

Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, AgriBio & Tumor with Executive and Consultant Guides 2020 to 2024

出版商 Howe Sound Research 商品編碼 567248
出版日期 內容資訊 英文 485 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全基因&EXOME定序的全球市場:研究、臨床、DTC、農業生物技術、癌細胞用途 Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, AgriBio & Tumor with Executive and Consultant Guides 2020 to 2024
出版日期: 2019年11月02日內容資訊: 英文 485 Pages
簡介

本報告提供全球全基因及EXOME定序的市場調查,市場及技術概要,各種相關經營者、組織、機關和所扮演的角色,各種用途與引進案例,產業結構,主要企業,市場成長的各種影響因素分析,企業及研究機關等的近幾年的配合措施,各地區/主要國家的實施數量、價格、收益規模的變化與預測,未來展望等資料彙整。

第1章 簡介、市場定義

第2章 市場概要

  • 相關經營者和作用
  • 用途、案例、討論
    • DTC
    • 研究
    • 臨床
    • 病原體檢驗
    • 農業生物技術
  • 產業結構
  • 主要企業的簡介

第3章 市場趨勢

  • 市場成長的促進要素
  • 市場成長的阻礙因素
  • 定序設備

第4章 WGES (全基因&EXOME定序):近幾年的發展

第5章 北美市場分析、預測

  • 數量、價格、收益:各用途、各國
    • 美國
    • 加拿大
      • 研究
      • 臨床
      • 農業生物技術
      • DTC檢驗
      • 癌細胞

第6章 歐洲市場分析、預測

  • 數量、價格、收益:各用途、各國
    • 法國
    • 德國
    • 英國
    • 西班牙
    • 義大利
    • 俄羅斯
    • 其他的歐洲、舊蘇聯
      • 研究
      • 臨床
      • 農業生物技術
      • DTC檢驗
      • 癌細胞

第7章 亞太地區市場分析、預測

  • 數量、價格、收益:各用途、各國
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 其他
      • 研究
      • 臨床
      • 農業生物技術
      • DTC檢驗
      • 癌細胞

第8章 南美、非洲、中東市場分析、預測

  • 數量、價格、收益:各用途、地區
    • 研究
    • 臨床
    • 農業生物技術
    • DTC檢驗
    • 癌細胞

第9章 全球市場分析、預測:摘要

  • 數量、價格、收益:各用途
    • 研究
    • 臨床
    • 農業生物技術
    • DTC檢驗
    • 癌細胞

第10章 全基因測序:未來的願景

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

OVERVIEW:

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Whole Genome Sequencing Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Whole Genome Sequencing Definition In This Report
    • 1.1.1 Whole and Exome Sequencing
    • 1.1.2 Research and Clinical
    • 1.1.3 Direct to Consumer
    • 1.1.4 AgriBio
    • 1.1.5 Tumor Cells
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing
  • 1.5 Sizing the Genome - Not What You Think
    • 1.5.1 Cost, Price and Genome Size, Pricing Practice
      • 1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Instrument Manufacturer
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Sequencing Labs
    • 2.1.10 Audit body
  • 2.2 Whole Genome Sequencing -Markets, Examples and Discussion
    • 2.2.1 Direct to Consumer - Two Approaches
      • 2.2.1.1 The New Age of Medical Information
      • 2.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 2.2.1.3 Newborn and Prenatal - A Brave New World
      • 2.2.1.4 DTC - How Many Segments?
    • 2.2.2 Research Markets
      • 2.2.2.1 Research Funding and Capital Expense
      • 2.2.2.2 WGS Datasets Preferred
      • 2.2.2.3 Existing research repurposed
      • 2.2.2.4 Organism Wide Market
      • 2.2.2.5 Service Suppliers Respond
    • 2.2.3 Clinical - Understanding Germline and Somatic
      • 2.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 2.2.4 Pathogen Testing
      • 2.2.4.1 The Hepatitis C Story
      • 2.2.4.2 Will the Microbiology Department Disappear?
    • 2.2.5 AgriBio - Big Business
      • 2.2.5.1 GMO is Here to Stay
      • 2.2.5.2 WGS Benefits and Risks
      • 2.2.5.3 The New Agriculture
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.3 Instrument Manufacturer Role
    • 2.3.4 Healthcare Industry Impacts - Still Struggling
      • 2.3.4.1 Can the Healthcare Industry Adapt?
      • 2.3.4.2 Genetic Counselling as an Industry
      • 2.3.4.3 WGES Adoption and Cannibalization
      • 2.3.4.4 The Meaning of Grail

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Diagnostic Factors
    • 3.1.2 Interpreting the Code Otherwise.
    • 3.1.3 Changes in Agriculture.
    • 3.1.4 Fertility Technology Comes of Age
    • 3.1.5 Pathogen Challenges
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Healthcare Cost Concerns Curtail Growth.
    • 3.2.4 Wellness has a downside
    • 3.2.5 GMO Opposition Movement.
  • 3.3 Sequencing Instrumentation
    • 3.3.1 Instrumentation Tenacity.
    • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
    • 3.3.4 Oxford Nanopore
      • 3.3.4.1 What is Oxford Nanopore Sequencing?
      • 3.3.4.2 What can Oxford Nanopore Sequencingt be used for?
      • 3.3.4.3 Oxford Nanopore Products
    • 3.3.5 Long Reads - Further Segmentation
    • 3.3.6 Linked Reads
    • 3.3.7 Targeted Sequencing Adopts CRISPR
    • 3.3.8 New Sequencing Technologies

4. WGES Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • UK Whole-Genome Sequencing Project Obtains £200M
      • WGS may help with disease outbreaks
      • Veritas Cuts WGS Price by 40%
      • Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
      • Machine-learning system used to diagnose genetic diseases
      • Whole Genome Sequencing for healthy creates controversy
      • 100,000 whole genomes sequenced in the NHS
      • Nebula Genomics Offers FREE Whole Genome Sequencing
      • Veritas Genetics has time limited WGS offer for $199
      • Veritas Genetics Launches Two New Whole Genome Sequencing Products
      • BGI unveils a powerful new sequencer
      • State of California Funds $2M Whole-Genome Sequencing Pilot
      • Rapid genome sequencing could revolutionize health care
      • Human Longevity Launches Whole Genome Product, MassMutual Partnerships $1500 to sequence newborns in China
      • Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
      • PerkinElmer Launches Clinical Whole Genome Sequencing Services
      • Nine Centres use Oxford Nanopore MinION to Sequence Human Genome
      • Esperite and BGI Genomics sign a strategic agreement to offer Whole Genome Sequencing on a large scale
      • Easily Affordable Whole-genome Sequencing is Goal of Mayo Collaboration with Veritas
      • Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples
      • MedGenome Expands Its NGS Capabilities and Forays Into Single-Cell Sequencing
      • Genomics England Adopts Edico's Dragen For NGS Analysis
      • BGI Says It Will Slash Cost of Gene Testing to $300
      • Position Statement Spells Out Fetal Diagnostic Sequencing Recommendations
      • Dante Labs Announces 10,000 European Genome Project

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1 Global Market by Country
  • 6.2 Global Market by Application

7. Market Sizes by Application

  • 7.1 Research Market
  • 7.2 Clinical Market
  • 7.3 Tumor Market
  • 7.4 DTC WEGS Market
  • 7.5 Agribio & Other Market

8. Market Sizes by Coverage

  • 8.1 Genome Market
  • 8.2 Exome Market
  • 8.3 Other Coverage Market

9. Vision of the Future of Whole Genome Sequencing

Appendices

  • I. United States Medicare System: January 2019 laboratory Fees Schedule
  • II Methodology
  • II.1 Authors
  • II.2 Sources

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • TABLE 3 LAB SPENDING 2014 TO 2024
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Whole Genome Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 Roles of WGS in AgriBio
  • Table 9 The Factors Driving Growth
  • Table 10 Factors Limiting Growth
  • Table 11 - Listing of Current NGS Instrument Specifications
  • Table 12 Six New Sequencing Technologies
  • Table 13 Market by Country
  • TABLE 14 GLOBAL MARKET BY APPLICATION
  • TABLE 15 RESEARCH SEGMENT BY COUNTRY
  • TABLE 16 CLINICAL SEGMENT BY COUNTRY
  • TABLE 17 TUMOR SEGMENT BY COUNTRY
  • TABLE 18 DT WGES SEGMENT BY COUNTRY
  • TABLE 19 AGRI/OTHER SEGMENT BY COUNTRY
  • TABLE 20 GENOME SEGMENT BY COUNTRY
  • TABLE 21 EXOME SEGMENT BY COUNTRY
  • TABLE 22 OTHER COVERAGE SEGMENT BY COUNTRY
  • Table 23 2019 Clinical Lab Fee Schedule

Table of Figures

  • FIGURE 1 CLINICAL LAB SPENDING 2014 TO 2024
  • Figure 2 Size of Genome for Various Species
  • Figure 3 - Cost To Sequence a Human Genome
  • FIGURE 4 APPLICATION SHARE BY YEAR
  • FIGURE 5 APPLICATION SEGMENT GROWTH RATES
  • FIGURE 6 SEGMENT SHARE SHIFTS
  • FIGURE 7 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 8 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 9 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 10 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 11 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 12 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 13 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 14 SEGMENT VS. TOTAL MARKET GROWTH
Back to Top